4:27 PM
 | 
Feb 09, 2010
 |  BC Extra  |  Company News

FDA extends gabapentin review by two days

XenoPort Inc. (NASDAQ:XNPT) said FDA extended the PDUFA date for an NDA for Horizant gabapentin enacarbil ( XP13512,

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >